نتائج البحث - "Glucagon-Like Peptide-1 Receptor"

1

Efficacy of once‐daily glucagon‐like peptide‐1 receptor agonist lixisenatide as an add‐on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual‐level pooled analysis of phase III studies

المؤلفون: Fuqiang Liu, Huiqiu Yin, Li Chen, Yuan Liu, Nan Cui, Minlu Zhang, Guangyu Wu, Xia Zhang, Minzhi Liu

المصدر: Journal of Diabetes Investigation, Vol 12, Iss 8, Pp 1386-1394 (2021)
Journal of Diabetes Investigation

مصطلحات موضوعية: Blood Glucose, Male, Endocrinology, Diabetes and Metabolism, Glucagon‐like peptide‐1 receptor agonist, 030204 cardiovascular system & hematology, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Medicine, Insulin, General Medicine, Articles, Middle Aged, Postprandial, Clinical Science and Care, Treatment Outcome, Original Article, Drug Therapy, Combination, Female, Adult, medicine.medical_specialty, Lixisenatide, 030209 endocrinology & metabolism, Glucagon-Like Peptide-1 Receptor, White People, Pooled analysis, Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, Asian People, Double-Blind Method, Diabetes mellitus, Internal medicine, Internal Medicine, Humans, Hypoglycemic Agents, Glycemic, Aged, Glycated Hemoglobin, business.industry, Type 2 Diabetes Mellitus, medicine.disease, RC648-665, Confidence interval, chemistry, Diabetes Mellitus, Type 2, Hyperglycemia, Glycated hemoglobin, business, Peptides, Body mass index

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6cd71b3f19c79c4974b2141f54e2167eTest
https://doaj.org/article/fffcb0cdaaaa4cfcac5061e371be5ef1Test

2

Heart failure outcomes and glucagon-like peptide-1 receptor agonists: A systematic review of observational studies

المؤلفون: Ali Aldossary, Basmah Alomrani, Mashael Alfaifi, Haifa A. Alsuhaibani, Omar S. Alkhezi, Amal A. Alhadyab, Osamah M. Alfayez

المصدر: Primary Care Diabetes. 15:761-771

مصطلحات موضوعية: medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, medicine.medical_treatment, 030209 endocrinology & metabolism, Glucagon-Like Peptide-1 Receptor, 03 medical and health sciences, 0302 clinical medicine, Diabetes mellitus, Internal medicine, Internal Medicine, medicine, Humans, Hypoglycemic Agents, Multicenter Studies as Topic, 030212 general & internal medicine, Glucagon-like peptide 1 receptor, Heart Failure, Dipeptidyl-Peptidase IV Inhibitors, Nutrition and Dietetics, business.industry, Insulin, Type 2 Diabetes Mellitus, medicine.disease, Diabetes Mellitus, Type 2, Heart failure, Observational study, Family Practice, business, Exenatide, medicine.drug, Cohort study

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b80e43d2999b12ff96176dfe4d17699dTest
https://doi.org/10.1016/j.pcd.2021.04.005Test

3

Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials

المؤلفون: Olav W. Nielsen, Aldo P. Maggioni, Christopher L. Edwards, Marco Metra, Naoki Sato, Barry H. Greenberg, Faiez Zannad, Gad Cotter, Alexandre Mebazaa, Georg Ertl, Beth A. Davison, Alain Cohen-Solal, Ovidiu Chioncel, Stefanie Senger, John R. Teerlink

المساهمون: Momentum Research Inc. [Durham, NC, USA] (MRI), Marqueurs cardiovasculaires en situation de stress (MASCOT (UMR_S_942 / U942)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, University of California [San Francisco] (UC San Francisco), University of California (UC), Veterans Affairs Medical Center, San Francisco, California, Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Centre d'investigation clinique plurithématique Pierre Drouin [Nancy] (CIC-P), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Cardiovascular and Renal Clinical Trialists [Vandoeuvre-les-Nancy] (INI-CRCT), Institut Lorrain du Coeur et des Vaisseaux Louis Mathieu [Nancy], French-Clinical Research Infrastructure Network - F-CRIN [Paris] (Cardiovascular & Renal Clinical Trialists - CRCT ), Service de Cardiologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), IT University of Copenhagen (ITU), Università degli Studi di Brescia = University of Brescia (UniBs), Civic Hospital of Brescia, Service d'Anesthésie-Réanimation [AP-HP Hôpitaux Saint-Louis Lariboisière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Lariboisière-Fernand-Widal [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), University of Medicine and Pharmacy 'Carol Davila' Bucharest (UMPCD), University of California [San Diego] (UC San Diego), Associazione Nazionale Medici Cardiologi Ospedalieri [Firenze] (ANMCO), University of Würzburg = Universität Würzburg, Nippon Medical School [Tokyo, Japon], Hôpital Lariboisière-Fernand-Widal [APHP], leboeuf, Christophe

المصدر: American Heart Journal
American Heart Journal, 2021, 240, pp.73-80. ⟨10.1016/j.ahj.2021.06.001⟩
Cotter, G, Davison, B A, Edwards, C, Senger, S, Teerlink, J R, Zannad, F, Nielsen, O W, Metra, M, Mebazaa, A, Chioncel, O, Greenberg, B H, Maggioni, A P, Ertl, G, Sato, N & Cohen-Solal, A 2021, ' Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials ', American Heart Journal, vol. 240, pp. 73-80 . https://doi.org/10.1016/j.ahj.2021.06.001Test

مصطلحات موضوعية: medicine.medical_specialty, 030204 cardiovascular system & hematology, Glucagon-Like Peptide-1 Receptor, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Heart Failure, Humans, Hypoglycemic Agents, Regression Analysis, Sodium-Glucose Transporter 2 Inhibitors, Treatment Outcome, 03 medical and health sciences, 0302 clinical medicine, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Internal medicine, Diabetes Mellitus, medicine, Treatment effect, 030212 general & internal medicine, business.industry, medicine.disease, Random effects model, Differential effects, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Heart failure, Cardiology and Cardiovascular Medicine, business, Type 2, Mace